Clinical Trials Logo
  1. Home
  2. Acute Ischemic Stroke
  3. NCT05198323

A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT

Acute Ischemic Stroke Clinical Trial

Official title:
A Phase II, Two-Part, Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects With Acute Ischemic Stroke (AIS) Undergoing Endovascular Thrombectomy (EVT)

Clinical Trial Summary

A phase IIb clinical study to evaluate the safety and efficacy of single or multiple doses of LT3001 drug product in subjects with acute ischemic stroke (AIS) undergoing endovascular thrombectomy (EVT).

Clinical Trial Description

This is a 2-part, multicenter, double-blind, randomized, and placebo-controlled prospective Phase II clinical study, designed to evaluate LT3001 drug product versus placebo in subjects with AIS undergoing EVT. Subjects who participate in this trial should be treated with standard of care (SoC) of AIS therapies when appropriate. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05198323
Study type Interventional
Source Lumosa Therapeutics Co., Ltd.
Contact Claire Sun
Phone +886-2-26557918
Email claire_sun@lumosa.com.tw
Status Not yet recruiting
Phase Phase 2
Start date February 1, 2022
Completion date April 30, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT04069546 - The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency N/A
Active, not recruiting NCT05700097 - Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy Phase 2
Recruiting NCT04415164 - Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke Phase 4
Completed NCT05429658 - Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System N/A
Recruiting NCT05390580 - Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct N/A
Recruiting NCT05070260 - Adaptive Efficacy and Safety Study of Glenzocimab Used as an add-on Therapy on Top of Standard of Care un the 4.5 Hours Following an Acute Ischemic Stroke Phase 2/Phase 3
Active, not recruiting NCT05547412 - Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
Completed NCT03366818 - New Stent Retriever, VERSI System for AIS N/A
Not yet recruiting NCT04984577 - Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke Phase 2
Completed NCT02223273 - Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke) N/A
Completed NCT02586233 - Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke Phase 1/Phase 2
Not yet recruiting NCT01594190 - Physical Activity Immediately After Acute Cerebral Ischemia N/A
Terminated NCT01694381 - Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor Early Phase 1
Completed NCT01120301 - Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3) Phase 3
Completed NCT00963989 - Imaging Guided Patient Selection for Interventional Revascularization Therapy N/A
Completed NCT01021319 - Identification of Stroke Patients ≤ 3 and ≤ 4.5 Hours of Symptom Onset by Fluid Attenuated Inversion Recovery (FLAIR) Imaging and Diffusion Weighted Imaging (DWI)
Recruiting NCT00710164 - Effectiveness and Safety of Xiaoshuanchangrong (XSCR) Capsule for the Treatment of Patients Who Have Suffered From a Stroke Phase 2/Phase 3
Active, not recruiting NCT04072705 - Clopidogrel Preventive Effect Based on CYP2C19 Genotype in Ischemic Stroke
Recruiting NCT05492474 - Cranial Ultrasound for Prehospital ICH Diagnosis N/A
Completed NCT04240470 - Endovascular Stroke Treatment Only (ESTO) Trial N/A